Royality Med's mission is to fast-track the early stage of drug discovery using our predictive models of the human brain for therapeutic success. Many neurodevelopmental diseases do not have treatments due to a lack of a-priori knowledge of the underlying biology. Royality Med's technology is able to model these diseases to help enable the discovery of new targets and drugs, de-risking the current failure-prone cumbersome approach.
For inquiries, please contact us at
E-mail: info@royalitymed.com
Leadership
The Royality Med's Scientific Team
Our senior leadership is comprised of practicing scientists and strategists, and whether they are working collaboratively or independently, they always do so in pursuit of therapeutic success.
Pablo Legorreta, Ph.D.
CEO & Chairman
Terrance Coyne, Ph.D.
Chief Financial Officer
Christopher Hite, Ph.D.
Vice Chairman
Mr. Chris T Williams, Ph.D.
Procurement Officer
Marshall Urist, Ph.D.
Head of Research & Investments
Mr Richard Kimbo, Ph.D.
Purchase Manager
George Lloyd, Ph.D.
Chief Legal Officer & Investments
Arthur McGivern, M.D., Ph.D.
General Counsel & Investments
Ashwin Pai, Ph.D.
Investments
Jim Reddoch, M.D.
Chief Scientific Officer & Investments
I would like to learn about Royality Med’s Pharmaceuticals discoveries to treat genetic diseases.